Skip to main content

Table 1 FDA approved ALK inhibitors for non-small cell lung cancer

From: Second- and third-generation ALK inhibitors for non-small cell lung cancer

Trials Patients Agents No. ORR PFS P value Refs.
Phase III
PROFILE1007
Relapsed
refractory
Crizotinib vs pemetrexed/docetaxel 173
174
65 %
20 %
7.7 ms
3.0 ms
<0.001 [13]
Phase III
PROFILE1014
Untreated Crizotinib vs chemotherapy 172
171
74 %
45 %
10.9 ms
7.0 ms
<0.001 [36]
Phase I Failed chemotherapy and crizotinib Ceritinib (NSCLC, ≥400 mg) 114 58 % 7.0 ms N/A [63]
Phase I/II Failed chemotherapy and crizotinib Alectinib (phase II) 46 94 % NA N/A [67]
Phase I/II Failed chemotherapy and crizotinib Alectinib (phase II) 47 55 % NA N/A [68]
  1. Abbreviations: N/A not applicable, No. number, ORR overall response rate, DOR duration of response, PFS progression-free survival, Ref reference, wks weeks, ms months